Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Dermatologic 1CNS 1

Conditions

Melanoma 1Glioblastoma 1Carcinoma, Medullary 1

Interventions

Temozolomide 80Radiotherapy 41Bevacizumab 35Radiosurgery 23Magnetic Resonance Spectroscopy 20Cyclophosphamide 17Radiation 14Irinotecan 13Carboplatin 12Topotecan 11Nivolumab 11Lomustine 11Filgrastim 10Everolimus 10Etoposide 10Erlotinib Hydrochloride 10pembrolizumab 9Radiotherapy, Intensity-Modulated 9Ipilimumab 9Granulocyte Colony-Stimulating Factor 8Carmustine 8antineoplaston AS 2-1 7antineoplaston A10 7Surgical Procedures, Operative 7Mental Status and Dementia Tests 7Isotretinoin 7Granulocyte-Macrophage Colony-Stimulating Factor 7sargramostim 6Vincristine 6TPI-287 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × rovalpituzumab tesirine × CNS × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡